Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089848 | 0.89 | HRH3 (0.47) | HRH3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL30379018 | 0.89 | HRH3 (0.47) | HRH3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL4032242 | 0.82 | HRH3 (0.55) | HRH3GPR119 | |
| SCHEMBL4033533 | 0.81 | HRH3 (0.56) | HRH3GPR119MEN1KMT2A | |
| SCHEMBL26090350 | 0.81 | LGMN (0.54) | MEN1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL30378807 | 0.81 | LGMN (0.54) | MEN1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL1938707 | 0.79 | SMN1; SMN2 (0.48) | HRH3GPR119MEN1MAPTTSHR | |
| SCHEMBL5209150 | 0.78 | HRH3 (0.60) | HRH3GPR119 | |
| SCHEMBL5210664 | 0.77 | HRH3 (0.61) | HRH3GPR119 | |
| SCHEMBL22629268 | 0.77 | HRH3 (0.53) | HRH3GPR119MEN1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4419520-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023069514-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069514-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | ADRM1, PSMD7, UBQLN2 | HRH3 4069/4885FFAR4 4540/4885GPR119 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.